Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raheela

Showing results (421-430 of 437) with videos related to

Pageof 44
Sort By:
Plos One|November 5, 2016
Mutation in LIM2 Is Responsible for Autosomal Recessive Congenital CataractsBushra Irum, Shahid Y Khan, Muhammad Ali, et al.
The Journal of Urology|July 21, 2009
p53 predictive value for pT1-2 N0 disease at radical cystectomyShahrokh F Shariat, Yair Lotan, Pierre I Karakiewicz, et al.
Molecular and Biochemical Parasitology|June 20, 2024
Pyridopyrimidinones as a new chemotype of calcium dependent protein kinase 1 (CDPK1) inhibitors for CryptosporidiumElise Waldron-Young, Wissarut Wijitrmektong, Ryan Choi, et al.
The Journal of Infectious Diseases|May 20, 2014
Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndromeZiad A Memish, Jaffar A Al-Tawfiq, Hatem Q Makhdoom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2026
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743Arnaud Scherpereel, Paul Baas, Anna K Nowak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2026
Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743Arnaud Scherpereel, Paul Baas, Anna K Nowak, et al.
BJU International|November 13, 2010
Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional studyCarmen Mir, Shahrokh F Shariat, Theodorus H van der Kwast, et al.
The American Journal of Pathology|March 26, 2003
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarraysChristine A Iacobuzio-Donahue, Anirban Maitra, Mari Olsen, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2004
HER-2 gene amplification can be acquired as breast cancer progressesSongdong Meng, Debasish Tripathy, Sanjay Shete, et al.
The Lancet. Oncology|April 26, 2017
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trialRobert L Coleman, Mark F Brady, Thomas J Herzog, et al.
Pageof 44

Showing results (421-430 of 437) with videos related to

Sort By:
Pageof 44
Plos One|November 5, 2016
Mutation in LIM2 Is Responsible for Autosomal Recessive Congenital CataractsBushra Irum, Shahid Y Khan, Muhammad Ali, et al.
The Journal of Urology|July 21, 2009
p53 predictive value for pT1-2 N0 disease at radical cystectomyShahrokh F Shariat, Yair Lotan, Pierre I Karakiewicz, et al.
Molecular and Biochemical Parasitology|June 20, 2024
Pyridopyrimidinones as a new chemotype of calcium dependent protein kinase 1 (CDPK1) inhibitors for CryptosporidiumElise Waldron-Young, Wissarut Wijitrmektong, Ryan Choi, et al.
The Journal of Infectious Diseases|May 20, 2014
Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndromeZiad A Memish, Jaffar A Al-Tawfiq, Hatem Q Makhdoom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2026
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743Arnaud Scherpereel, Paul Baas, Anna K Nowak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2026
Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743Arnaud Scherpereel, Paul Baas, Anna K Nowak, et al.
BJU International|November 13, 2010
Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional studyCarmen Mir, Shahrokh F Shariat, Theodorus H van der Kwast, et al.
The American Journal of Pathology|March 26, 2003
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarraysChristine A Iacobuzio-Donahue, Anirban Maitra, Mari Olsen, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2004
HER-2 gene amplification can be acquired as breast cancer progressesSongdong Meng, Debasish Tripathy, Sanjay Shete, et al.
The Lancet. Oncology|April 26, 2017
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trialRobert L Coleman, Mark F Brady, Thomas J Herzog, et al.
Pageof 44